Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes.
SMS 201-995 (Sandostatin) was studied using low doses (50 to 100 micrograms) administered subcutaneously every 12 hours. A single 50-micrograms dose of SMS 201-995 effectively controlled gastric acid and blood gastrin levels for 12 hours in three patients with benign gastrinomas and was useful in their perioperative management. Higher doses of the agent (500 to 800 micrograms per day) had no effect on metastases in one of two patients with metastatic gastrinoma. In the other patient, one tumor shrank but the other continued to grow after three months of treatment while serum gastrin levels did not change. Cultured metastatic tumor tissue from this patient released different forms of gastrin; growth rates varied, independent of uptake of SMS 201-995, and gastrin release increased. A neonate with nesidioblastosis maintained normal blood glucose levels while receiving SMS 201-995 therapy following a 95 percent pancreatic resection. In two elderly patients with organic hypoglycemia--one with a single benign adenoma and one with multiple adenomatosis--the somatostatin analogue did not prolong the hypoglycemia-free interval. In nine patients with carcinoid syndrome, flushing was uniformly controlled with 50 micrograms of SMS 201-995 administered every eight to 12 hours. One of the nine required exocrine pancreatic replacement. After six months of treatment, three of the nine had no change in tumor size and one had remission of symptoms and stopped treatment. In two patients with vipoma, SMS 201-995 controlled diarrhea and reduced levels of vasoactive intestinal peptide; tumor necrosis occurred in one patient. In a patient with diabetic diarrhea unresponsive to all treatments, SMS 201-995 therapy controlled the diarrhea but did not interfere with control of the diabetes.
D000236:Adenoma / Q000188:drug therapy; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D048909:Diabetes Complications; D003967:Diarrhea / Q000188:drug therapy*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D006946:Hyperinsulinism / Q000188:drug therapy; D007340:Insulinoma / Q000188:drug therapy; D008297:Male; D008303:Malignant Carcinoid Syndrome / Q000188:drug therapy; D008875:Middle Aged; D015282:Octreotide; D010182:Pancreatic Diseases / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003969:Vipoma / Q000188:drug therapy; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy / Q000378:metabolism
D000970:Antineoplastic Agents; D013004:Somatostatin; D015282:Octreotide